9805579-1
IPOS copy.

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 31/40 — A1

(11) International Publication Number: WO 97/40830

(43) International Publication Date: 6 November 1997 (06.11.97)

(21) International Application Number: PCT/US97/07752

(22) International Filing Date: 1 May 1997 (01.05.97)

(30) Priority Data:
60/016,658 — 1 May 1996 (01.05.96) — US
Not furnished — 30 April 1997 (30.04.97) — US
withdrawn

(71) Applicant *(for all designated States except US)*: ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, IN 46285 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: JIROUSEK, Michael, R. [US/US]; 10342 Fawn Ridge Lane, Indianapolis, IN 46236 (US). VIGNATI, Louis [US/US]; 5617 North Meridian, Indianapolis, IN 46208 (US). WAYS, Douglas, Kirk [US/US]; 4565 North Park Avenue, Indianapolis, IN 46205 (US).

(74) Agents: SKERPON, Joseph, M. et al.; Banner & Witcoff, Ltd., Suite 1100, 1001 G Street, N.W., Washington, DC 20001 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: THERAPEUTIC TREATMENT FOR VEGF RELATED DISEASES

(57) Abstract

A method for inhibiting VEGF stimulated endothelial cell growth, such as associated with neoplasia, and VEGF stimulated capillary permeability, such as associated with pulmonary edema are disclosed, particularly using the β-isozyme selective PKC inhibitor, (S)-3,4-[N,N'-1,1'-((2''-ethoxy)-3'''(O)-4'''-(N,N-dimethylamino)-butane)-bis-(3,3'-indolyl)]-1(H)-pyrrole-2,5-dione hydrochloride salt.